Aktuellt
SENASTE
Redeye comments on Immunicum’s Q1 2022 report, which we judge came without any major surprises. We believe additional ADVANCE II readouts in Q2 and Q4 of this year represent the primary potential positive catalysts for the share. Additionally, we suspect that the company will need to address financing before year-end.
LÄS MER
